Compare Neurocrine Biosciences Inc (NBIX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Toyota Motor Corp — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Toyota Motor Corp trades at $194.17 (market cap $228.43B). The key difference: Toyota Motor Corp is far larger — about 14.5× Neurocrine Biosciences Inc's market cap, and Toyota Motor Corp pays a 3.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TM | |
|---|---|---|
Market Cap | $15.77B | $228.43B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $248.29 |
52-Week Low | $123.10 | $166.50 |
Enterprise Value | $15.78B | $427.29B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Toyota Motor (TM) trades at $191.45, down 2.87% amid bearish technical signals, though fundamentals remain strong with attractive valuation metrics including a P/E of 8.51 and P/S of 0.74. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $7.57 exceeding estimates by 62%. Recent news highlights strong demand for hybrid models like the RAV4 and strategic partnerships, though tariff threats and a global recall present headwinds.
TM offers value with solid profitability and growth, but faces near-term technical pressure and geopolitical risks. The stock's undervaluation relative to DCF estimates around $342 presents opportunity, yet investors must weigh competitive pressures and macroeconomic uncertainties against the company's operational strength and market leadership in hybrid technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
